Study of Tamoxifen And Raloxifene (STAR)

Introduction

Study characteristics:

• 19,747 post menopausal women
• > 50% s/p hysterectomy

Treatment:

• 9745 women received raloxifene
• 9726 women received taxoxifen

Follow-up of 5 years

Primary endpoint:

• myocardial infarction, stroke, or cardiovascular death

Results:

• no difference in breast cancer incidence: raloxifene: 167 of 9745, tamoxifen: 163 of 9726
• fewer uterine cancers with raloxifene vs tamoxifen, mostly endometrial cancer (those with a uterus): 23 of 4,712 vs 36 of 4732
• fewer deep vein thrombosis with raloxifene vs tamoxifen: 65 of 9,745 vs 87 of 9,726
• fewer pulmonary embolisms with raloxifene vs tamoxifen: 35 of 9,745 vs 54 of 9,726
• no difference in stroke incidence: 51 of 9745 vs 53 of 9726 or deaths from stroke 4 of 9745 vs 6 of 9726
• fewer dutal or lobular breast carcinoma in situ with tamofen than raloxifene: 57 of 9726 vs 81 of 9745
• more gynecologic problems, vasomotor symptoms, leg cramps, bladder problems in tamoxifen group
• more musculoskeletal pain, dypareunia, weight gain in raloxifene group
• no differences in osteoporosis, ischemic heart disease, stroke

This confirms results of the CORE trial.

It has previously been found that tomxifen reduces the risk of breast cancer in postmenopausal women relative to placebo.

More general terms

• clinical trial

Additional terms

• MORE-CORE trial
• raloxifene (Evista)
• tamoxifen (Novaldex, Soltamox)